공시 • Jan 20
Scopus BioPharma Files Form 15 Scopus BioPharma Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share. 공시 • Nov 08
Scopus BioPharma Inc. Presents DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Scopus BioPharma Inc. and its majority-owned subsidiary, Duet BioTherapeutics Inc., presented compelling new data that DUET-102 in combination with PD-1 blockade demonstrates significant anti-tumor activity in models of malignant glioma. The new data was presented on November 4, 2023 at the 38th Annual Meeting of the Society for Immunotherapy of Cancer ("SITC") by Marcin Kortylewski, Ph.D. Dr. Kortylewski, Professor of Immuno-Oncology at City of Hope, is the Co-Founder and Senior Scientific Advisor of Duet. Duet is developing novel immunotherapies to overcome treatment-resistant cancers. DUET-102 is a double-stranded antisense oligonucleotide ("ASO") STAT3 inhibitor linked to a TLR9 immune activator being developed for the treatment of glioma. Glioma is a common type of tumor originating in the glial cells of the brain. Approximately 20,000 patients are diagnosed in the United States annually, with such patients having a 5-year survival rate of less than 7%, reflecting the need for new therapies to combat this disease. The featured data shows: Intracranially injected DUET-102 sensitizes malignant glioma to systemic PD-1 blockade, triggering complete injection of both orthotopic GL261 and PD-1 refractory QPP8 tumors in the majority of treated mice. DUET-102 creates ideal conditions for PD-1 blockade to recruit cancer-killing effector CD8 positive T cells into the tumor by activating intratumoral dendritic cells, M1 macrophages, and microglia, while concurrently reducing immunosuppressive tumor-associated M2 macrophages, resting microglia, and regulatory T cells. DUET-102, as a monotherapy, inhibited tumor growth and extended survival of mice in U251, GL261, and QPP8 models of glioma. DUET-102 was well tolerated and demonstrated unique suitability for intracranial injection, with optimized activity and tolerability in the brain compared to single-stranded ASO designs. Furthermore, the effectiveness of DUET-102 in releasing immunosuppression may enhance the efficacy of other T-cell based immunotherapies in the context of glioma, including potential combinations of DUET-102 with adoptive cell transfer therapies, such as CAR T-cell therapies. 공시 • Dec 17
Scopus BioPharma Inc. Announces Update on Deficiency Notification Letters from Nasdaq Regarding Minimum Bid Price Requirement As previously disclosed, Scopus BioPharma Inc. has not satisfied certain requirements for continued listing of the Nasdaq Stock Market LLC (“Nasdaq”), including: (i) the minimum Market Value of Listed Securities; (ii) the minimum Market Value of Publicly Held Shares; and (iii) the minimum closing bid price. As also previously disclosed, the Company had a hearing, on August 25, 2022, with the Nasdaq Hearings Panel (the “Panel”) at which the Panel considered the Company’s plan for regaining compliance with Nasdaq listing standards (the “Compliance Plan”). By letter dated September 13, 2022, Nasdaq informed the Company of the Panel’s decision directing that the Company’s listing be transferred to the Nasdaq Capital Market and that the Company’s common stock would continue to be listed on that market subject to, among other things, the Company satisfying the Compliance Plan. As reported on December 2, 2022, the Company failed to comply with, among other things, milestone dates included in the Compliance Plan. In response to the Company informing the Panel of an inability to complete a specified financing transaction by a subsequent milestone date, the Panel informed the Company, by letter dated December 15, 2022, of its determination to delist the Company’s common stock from Nasdaq. Such letter further informed the Company that Nasdaq will complete the delisting after, among other things, the lapsing of applicable appeal periods and that trading of the Company’s common stock on Nasdaq will be suspended effective at the open of trading on December 19, 2022. The Company anticipates that, upon suspension of trading on Nasdaq, its common stock will commence trading on one of the markets operated by the OTC Markets Group under its existing ticker symbol SCPS". The Company has submitted an application for trading of its common stock on the OTCQB Venture Market (the OTCQB"). The OTCQB requires, among other things, that companies be current with and otherwise satisfy applicable reporting requirements. The Company intends to continue to comply with applicable reporting requirements under the Securities Exchange Act of 1934. There can be no assurance that the Company's application to trade on the OTCQB will be approved on a timely basis or at all or that the Company will be able to satisfy reporting and other applicable requirements. 공시 • Dec 05
Scopus BioPharma Inc. Announces Update on Deficiency Notification Letters from Nasdaq Regarding Minimum Bid Price Requirement As previously reported, Scopus BioPharma Inc. (the ‘company’) received deficiency notification letters from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (‘Nasdaq’ or the ‘Exchange’) indicating that the Company was not in compliance with Nasdaq’s ‘minimum bid price’ requirement, which requires that the bid price of the stock of listed companies be at least $1.00 per share (the ‘Minimum Bid Price Requirement’) and certain Nasdaq listing rules relating to maintaining a minimum market value of listed securities of $50,000,000 (the ‘MVLS Requirement’) and a minimum market value of publicly held shares of $15,000,000 (the ‘MVPHS Requirement’ and, together with the Minimum Bid Price Requirement and the MVLS Requirement, the ‘Listing Requirements’). Also, as previously disclosed, the Company participated in a hearing on August 25, 2022 with the Nasdaq Hearings Panel (the ‘Panel’) at which the Panel considered the Company’s plan for regaining compliance with Nasdaq listing standards (the ‘Compliance Plan’). Also, as previously disclosed, on September 13, 2022, Nasdaq informed the Company of the Panel’s decision (the ‘Decision’) directing that the Company’s listing be transferred to the Nasdaq Capital Market, effective at the open of business on September 15, 2022, and the Company’s common stock will continue to be listed on that market subject to, among other things, the Company satisfying the Compliance Plan in full by no later than January 9, 2023. The Company failed to comply with milestone dates set forth in the Compliance Plan and did not timely inform Nasdaq of such failure. By letter dated December 1, 2022, Nasdaq informed the Company that the Panel has determined to grant the Company a final extension to such milestone dates and publicly reprimanded the Company. Such public reprimand, pursuant to Listing Rule 5815(c)(1)(D), was issued to the Company for its failure to comply with Listing Rule 5250(a)(1), requiring it to notify Nasdaq of certain significant developments that led to its prior representations about its ability to satisfy the terms of the Decision and, therefore, the Exchange’s continued listing requirements being inaccurate. While the Company is continuing to use its best efforts to satisfy the Listing Requirements in full by no later than January 9, 2023, there can be no assurance that the Company will be able to do so as set forth in the Compliance Plan, as amended, or at all. Failure to do so would result in the delisting of the Company’s common stock from Nasdaq, which would likely have a material adverse effect on the trading and value of the Company’s common stock. 공시 • Nov 16
Scopus BioPharma Inc. announced delayed 10-Q filing On 11/15/2022, Scopus BioPharma Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Dave Buckel was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 